Condition: Advanced Pheochromocytoma and Paraganglioma · PCPG · Sponsor: Jazz Pharmaceuticals
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@jazzpharma.com
Always discuss trial participation with your own doctor first.
| UCLA | Los Angeles, California, United States | Recruiting |
| Stanford | Palo Alto, California, United States | Recruiting |
| U of Colorado | Aurora, Colorado, United States | Recruiting |
| U of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| Mayo-Rochester | Rochester, Minnesota, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Columbia University Medical Center | New York, New York, United States | Not Yet Recruiting |
| PENN | Philadelphia, Pennsylvania, United States | Recruiting |
| UTAH | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07282587